0001193125-13-363443.txt : 20130911 0001193125-13-363443.hdr.sgml : 20130911 20130911074852 ACCESSION NUMBER: 0001193125-13-363443 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20130911 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130911 DATE AS OF CHANGE: 20130911 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AxoGen, Inc. CENTRAL INDEX KEY: 0000805928 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 411301878 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36046 FILM NUMBER: 131089968 BUSINESS ADDRESS: STREET 1: 13859 PROGRESS BLVD. STREET 2: SUITE 100 CITY: ALACHUA STATE: FL ZIP: 32615 BUSINESS PHONE: (386) 462-6817 MAIL ADDRESS: STREET 1: 13859 PROGRESS BLVD. STREET 2: SUITE 100 CITY: ALACHUA STATE: FL ZIP: 32615 FORMER COMPANY: FORMER CONFORMED NAME: LECTEC CORP /MN/ DATE OF NAME CHANGE: 19920703 8-K 1 d596490d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2013

 

 

AXOGEN, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Minnesota   1-36046   41-1301878

(State or other jurisdiction

of incorporation)

  

(Commission

File Number

  

(IRS Employer

Identification No.)

 

13859 Progress Boulevard, Suite 100,

Alachua, Florida

   32615
(Address of Principal Executive Offices)   (Zip Cope)

Registrant’s telephone number, including area code (386) 462-6800

(Former name or former address if changed since last report,)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01 Other Information

On September 11, 2013, AxoGen, Inc. (the “Company”) issued a press release announcing that the underwriters of its recent public offering of common stock have exercised their option to purchase an additional 184,332 shares of common stock. In connection with the offering, the Company has now received aggregate gross proceeds of approximately $18.6 million, excluding deductions for underwriting discounts and commissions and estimated expenses. JMP Securities LLC acted as the sole book-running manager in the offering and Ladenburg Thalmann & Co. Inc., acted as co-manager.

A copy of the press release is filed herewith as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

 

Exhibit No.

   

Description

99.1    AxoGen, Inc. press release, dated September 11, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AXOGEN, INC.
Date: September 11, 2013   By:   /s/ Gregory G. Freitag
    Gregory G. Freitag
    Chief Financial Officer

EXHIBIT INDEX

 

Exhibit No.

   

Description

99.1    AxoGen, Inc. press release, dated September 11, 2013.
 EX-99.1 2 d596490dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

AxoGen, Inc. Announces Exercise of Over-Allotment Option

Exercise follows public offering and generates $18.6 million in proceeds

ALACHUA, FL – September 11, 2013 – AxoGen, Inc. (NASDAQ: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today announced that the underwriters of its recent public offering of common stock have exercised their option to purchase an additional 184,332 shares. The total gross proceeds to AxoGen from this offering, including from the exercise of the over-allotment option, are expected to be $18.6 million, excluding deductions for underwriting discounts and commissions and estimated expenses.

AxoGen will use the net proceeds from the offering to expand product commercialization and marketing efforts for its portfolio of peripheral nerve repair products (Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector); to further develop its product pipeline; and for general working capital purposes.

A registration statement relating to these securities has been declared effective by the SEC. The registration statement may be accessed through the SEC’s website at www.sec.gov. JMP Securities LLC acted as the sole book-running manager in the offering and Ladenburg Thalmann & Co. Inc. acted as co-manager. Copies of the final prospectus relating to this offering may be obtained from JMP Securities LLC, 600 Montgomery Street, 10th Floor, San Francisco, California 94111, Attention: Prospectus Department, (415) 835-8985.

About AxoGen, Inc.

AxoGen (NASDAQ: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that we believe will define their product categories. AxoGen’s products offer a full suite of surgical nerve repair solutions including Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, West Lafayette, Indiana, and are distributed exclusively by AxoGen. AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL. To receive email alerts directly from AxoGen, please click here www.axogeninc.com/emailalerts.html.

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and

marketing efforts for its portfolio of peripheral nerve repair products, Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector, product development, financial performance, sales growth, product adoption, market awareness of our products, data validation and our ability to maintain the listing of our common stock on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of the registration statement and the final prospectus.

Contact:

AxoGen, Inc.

Greg Freitag, Chief Financial Officer

386.462.6856

InvestorRelations@AxoGenInc.com

GRAPHIC 3 g596490g09k65.jpg GRAPHIC begin 644 g596490g09k65.jpg M_]C_X``02D9)1@`!`@$!+`$L``#_X0MB17AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````4````<@$R``(````4````AH=I``0````!````G````,@```$L```` M`0```2P````!061O8F4@4&AO=&]S:&]P(#@`P`$`````0```#8` M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H M``,````!``(```(!``0````!```!)@("``0````!```*-`````````!(```` M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43 M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X- M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P, M#`P,#`P,#`P,#`P,#/_``!$(`"D`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```! M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$` M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5 MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7 MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_ MV@`,`P$``A$#$0`_`/54SG-:TN<0&@22=``$B0`23`&I)7%]=Z]^T+#CTDC` MK/T08]9P_.>1_P!I_P!UGYZEP8)994-`/FEV8.9YF&"'%+61^6/[SJYGUD]0 M.^P.95CM.U_4+P2R>[,3';^ER[/ZOZ-9S.L='>_]>=G9A)]UCW;&`^+,6BRM MC6?V-ZQ'.MOL!,O>!#0T:-:.&L8W^;K3/KL9&]KF;OHR(F/!:4>5QQ%"Q_=- M2_QOFYS"#W:VPNV?V5 M;6-]4M_[%KW?1WV;/ZNX_P#?MRV"0T%SC`&I)X`69EB8Y)1OBX21;M8)"6*$ MJ$>*(EPC86NDAU9%%T^E8RR.=C@Z)_JHBC(K=E!!U&JDDDDE*247O96POL<& M,;JYSC``\R57Q^I]-RK#5BY=%]@Y978U[O\`-8XI*;22222E))))*?_0['ZW M]3=74WIM)AUXW7D=JYCT_P#KKO\`H+GL7"]5@NMW-I)+:F,_G+G-&ZQE,^UE M53!^GRG?HZ5<.+;UOZP9#2XMK-KFN>.U=?L:UG\MS6*YT_.P1]8;ADEE.+16 M[%PVO@5M:UP8YON]NZW:_P"FM2'ZK%P1%R$?-SOYW(?\`\8KF1AWXG3J,*QI^VYUX MNKQ^[&AIIKW-_,LN>_W?^8+:LS?J]TZP#I.-7E9[I]-M(#@/WG.N]S:ZVM^E ML3_5_IM^1E.ZSGN]6U_\PX\&=/5K;_H=OZ/'_D?I?\(E+/4>(Q,(#4"7SY)_ MHZ?N_P!94.5N?`)C).7IE*'\WAQ_I^K]_P#=A^@[73L-N#@TXC3/HL#2?$\O M=_:>LOZTYKA15TNC7(SW!A`Y#"0UW_;CO9_VXMQSFM:7.(:UHDD\`!<,SKF* M>NOZKEM>]C01C5MVR!]"MSM[F_F&Q_\`QEBJGY5=]A; M92W&8+'^H!J"=L,VN=[M_L6)]6\ECOK!9:WVUY#;G`&-`7-N$_V52>WI^1UL ML:\G`NR(W#31Y[?\%ZI^E_HE9R88Y,L^,&^&,^(?\Z/_`#6GBYF>+#C]LQHS MGCX9>/JA+^['B]3T_P#SJP6X0R[:[:Q82*:B&[[`WZ=C&AVWTF_Z1[D_3?K/ MAY^2,4UV8]KY],61#B!NVRWZ+]O[RQPQF=];6TEH%&._8RL#VAF.V6L#?W/6 M0NIW&SZRWW4Z''#G`CQHI<]W_3]JC.#%1'"0?;.:[^3]V+*.:SW$\0,?='+\ M/#_.G].?]7^JY/5LK,^N?UF'1L>[T^FTO>&1JR*M+\RQG^'>ZS]%B[_T;/\` MMQ0^LGU+RNCYF';]7:'M`X_Y]3$!EWUKQ?K'B=%S>KVVW/NI.1Z%FYH:X^M97[ZJW;OL M['?V%2=1[+K7URZ;T4U8][+,CJ%C6N.'0`Y[=W'J:[6;OS/\(]1Z+]=>E]6J MR2&68U^'6ZZ['M`W>FSZ=E;FG:[;]!_[BXGZO7=FX>[U&45>@S_`()%R,/K&*>M]YI^RZZI MQH??D>I8P%^UKS79C6%C`Y_I[&/K?_H[%5R^E]!S+[,FBS(<;';K*Z&DM+G< M^ZRO97O=_P`(NI3'D?'^"N`YO<](/N5ZN`^FK_2XHN=(``$#A.DH<_N<7 MK^G\I>KB_O-GE?:X/U7UV_[CTS\]K=@/T M_H?U$W2>DU8CV-99:)=8^-"YQGV[OS6_1:M!)(>Y[.G\WQ:U\W'_64?9^ M\>J_=X-.+Y/;O]%Y7*^JO4K,S(OQ[ZJF7O?`]P(99]-AVM_=1NH_5,V8^+3@ M/96[':YKWV3+B8>+/9/O]1=(DK/]+O'M_5V_=_3_`,%I?T"LMW_6OBOY_P#) M_P"'\SS5_P!7^L5Y_P"T<"^IF18)M!F&O'AX1Q<->Y[?Z'%_49,/W3WO3 MQ<7%+AX^+VO=_3X/T/Q MBT>C_47)Z=UG"ZG;EC*?4+K,U[]VY]UC376:@[?[&-L?ZEEMOJ6+L4E3=%X& MKZD_6CI&7D#ZOY]-6+D^S=9(L;7)=6QX]*YOJ4[W,KOK1+/\7=^/T+]G]/OJ M.9DWLOSLFT.:'MK#_2HK97ZCME=K]_O_`.$L7=))*>2ZE]4>HW_5;IW0L6ZE MC\5S'Y#W[]KBT/<[T]K2[W7V;_>M#IW1NI=-Z5TW`Q[V`XK0,DMT:YQ.^QS= MPW.KWN>MU))3_]G_[1`R4&AO=&]S:&]P(#,N,``X0DE-!"4``````!`````` M````````````````.$))30/M```````0`2P````!``$!+`````$``3A"24T$ M)@``````#@`````````````_@```.$))300-```````$````'CA"24T$&0`` M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X M0DE-)Q````````H``0`````````!.$))30/U``````!(`"]F9@`!`&QF9@`& M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4` M```!`"T````&```````!.$))30/X``````!P``#_____________________ M________`^@`````_____________________________P/H`````/______ M______________________\#Z`````#_____________________________ M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0` M````.$))300:``````.+````!@``````````````-@```*<````K`%``<@!E M`',`7!E M96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P````$` M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<````` M`````$)T;VUL;VYG````-@````!29VAT;&]N9P```*<````#=7)L5$585``` M``$```````!N=6QL5$585`````$```````!-'1415A4`````0``````"6AOD%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI8V56 M97)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````115-L M:6-E0D=#;VQO)E\K.$P]-UX_-&)Y2DA;25Q-3D M]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<' M!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C+RLX3#TW7C\T:4I(6TE<34Y/2EM<75 MY?569G:&EJ:VQM;F]B7I[?'_]H`#`,!``(1`Q$`/P#U5,YS6M+G M$!H$DG0`!(D`$DP!J25Q?7>O?M"PX])(P*S]$&/6I<&" M665#0#YI=F#F>9A@AQ2UD?EC^\ZN9]9/4#OL#F58[3M?U"\$LGNS$QV_IL1SK;[`3+W@0T-&C6CAK& M-_FZTSZ[&1O:YF[Z,B)CP6E'E<<10L?W34O\;YG'R<]EF>(@$=I#BA_B?)_W M;Z%@TX@J9?A/<:+&AS0'N`%F98F.24;XN$D6[6"0EBA*A'BB)<(V%KI(=611=/I6,LCG8X M.B?ZJ(HR*W900=1JI))))2DE%[V5L+['!C&ZN[_`#6.*2FTDDDDI22222G_T.Q^M_4W5U-Z;28=>-UY':N8]/\`ZZ[_ M`*"Y[%PO58+K=S:22VIC/YRYS1NL93/M954P?I\IWZ.E7#BV];^L&0TN+:S: MYKGCM77[&M9_++J\?NQH:::]S?S++GO]W_F"VK,W MZO=.L`Z3C5Y6>Z?3;2`X#]YSKOYOY MAL?_`,98JG+0E.YE9T9`W&I[F>W^MN6KA_6GI^57?86V4MQF"Q_J`:@G;#-KG>[?[%B?5O M)8[ZP66M]M>0VYP!C0%S;A/]E4GMZ?D=;+&O)P+LB-PTT>>W_!>J?I?Z)6Y/TWZSX>?DC%-=F/:^?3%D0X@;MLM^B_; M^\L<,9G?6UM):!1COV,K`]H9CMEK`W]SUD+J=QL^LM]U.AQPYP(\:*7/=_T_ M:HS@Q41PD'VSFN_D_=BRCFL]Q/$#'W1R_#P_SI_3G_5_JN3U;*S/KG]9AT;' MN]/IM+WAD:LBK2_,L9_AWNL_18N_]&S_`+<4/K)]2\KH^9AV_5VG*RGP7A[0 M'.JMK+#6[UF-J:QMV[Z#D7_%?5NSLV]L&ZO%K;6TF)]1SGN/^?4Q`9=]:\7Z MQXG1A9N:&N/K65^^JMV[[.QW]A4G4>RZU]RS(ZA M8UKCAT`.>W=QZFNUF[\S_"/4>B_77I?5JLDAEF-?AUNNNQ[0-WIL^G96YIVN MV_0?^XN)^KUW7.H]?S.M=*QJ,O,E]I&2XM96VXEE7IN'N]1E%7H,_P""1QS7+B>EU5X/^+OJF:6#U<][J6.(U+-S<.MH_J.]:QJW_`/%MBBKH#\B- MVPZ']'OLNNJ<:'WY'J6,!?M:\UV8UA8P.?Z>QC MZW_Z.Q5K@/IJ_TN*+G2'+^UZC$8N+T>Y&Y<5?H&,G!Z?\`5^LQZE`QL7\ZB=UM MW_AR_P#T/_=5GZ/_`$JW@`!`X3I*'/[G%Z_I_*7JXO[S9Y7VN#]5]=O^X]'# M_<:'6L3-S,%^+B/96ZT[;'/)'L_/:W8#]/Z']1-TGI-6!@UX]C666B76/C0N M<9]N[\UOT6K022'N>SI_-\6M?-Q_UE'V?O'JOW>#3B^3V[_1>5ROJKU*S,R+ M\>^JIE[WP/<"&6?38=K?W4;J/U3-F/BTX#V5NQVN:]]DRXF'BSV3[_472)*S M_2[Q[?U=OW?T_P#!:7]`K+=_UKXK^?\`R?\`A_,\U?\`5_K%>?\`M'`OJ9D6 M";09AKW-#;]FYC]];W>_W-5OHWU>&$Z[(S+!DY60"UYCV@.]UH]WT_5=]-ZV MDDS)]X]K7AX>$<7#7N>W^AQ?U&3#]T][T\7%Q2X>/B]KW?T^#]#W'SUW^+[Z MP=.SG6]!SV54F6UV.>^NUM9.[T;=C+67L8M'H_U%R>G=9PNIVY8RGU"ZS->_ M=N?=8TUUFH.W^QC;'^I9;;ZEB[%)4W1>!J^I/UHZ1EY`^K^?35BY/LW62+&U MR75L>/2N;ZE.]S*[ZT2S_%W?C]"_9_3[ZCF9-[+\[)M#FA[:P_TJ*V5^H[97 M:_?[_P#A+%W222GDNI?5'J-_U6Z=T+%NI8_%E=-P,>]@.*T#)+=&N<3OL&%P+69I;'1E#IX87!M971A('AM;&YS.G@])V%D;V)E.FYS.FUE=&$O)R!X.GAA<'1K M/2=835`@=&]O;&MI="`R+C@N,BTS,RP@9G)A;65W;W)K(#$N-2<^"CQR9&8Z M4D1&('AM;&YS.G)D9CTG:'1T<#HO+W=W=RYW,RYO&UL;G,Z:5@])VAT='`Z+R]N&UL;G,Z>&%P M34T])VAT='`Z+R]N&%P+S$N,"]M;2\G/@H@(#QX87!- M33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O`",`*``M`#(`-P`[`$``10!*`$\` M5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#! M`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0&!YD'K`>_!](' MY0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD M";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+ ML`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW> M#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,0 M81!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,# M$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6 M`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@ M&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L< MHQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!! M(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D M321\)*LDVB4))3@E:"67)<`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q! M[D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?` M2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*< M8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J M2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P M,QY*GF)>>=Z M1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K@%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+ MEHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2* ME/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP M0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@ MJ%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R M2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R; MO16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q MHM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFENV<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV M^_>*^!GXJ/DX^H6&AXB)BI25EI>8 MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R'EZ>W MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN]^Z]TWY7+8S!8VNS.:R%%B<3C*6:MR.3R-3# M1T-#1TZ&2>IJJJ=TA@@B1269B`![>MK:XO+B&UM('EN9&"JB@LS,<``#))/` M#I->WMIMUI<7]_T^IMT9?K7JG&3ZM,M#32[5Q(JLC2*?2)YJR%F47('L7OM?.VV0E?;WV% M@M+(#MFO84N[QQY,1,]%;STJA`X=1Y%OGMIOER&]W/O576X;DS=UMMMQ)8;= M&?-%-O'J=?(.TJDC)IU8/UU\=.H*/%X;=W2W8?8^/H:N.&OQFX=N]O[HWA@L MW"#=#78_5O:WD>"SL-[Y!YGW6*W6M)Y9X)5/! M@4KQ%5.0:VB2KCI($KYH:BL2-5J*BGA:GAGD7@RI`TDS0B2U].MM)-@2/<;2 MF,R.85*Q$X!-2!Z5H*T]:#J9H%G6&-;EU:<#N*C2"?4"II7TJ:>O4KVWT]U[ MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO M=>]^Z]U[W[KW7__0W^/?NO=(SL+L':'5FSL]OW?>:I-O[7VY0R5V3R58X551 M!:*GIX[ZZJNJY2(X(4!DEE8*H)/LUV/9-TYCW6RV79K1I]QN'"HBC]I)\E49 M9CA0"3CHAYGYFV/D[8MRYDYCW!+;9[2,O)(Q\AP51Q9V-%114LQ``J>M9_Y2 M?-/<'R=S$C[DES>T_CWBL@TFU^K,34K1;D[(JJ%_VZ[<^2C5TI:7R`&61O)3 MT*DQP)-57D7H%[=>TUE[>6JC;TANN>9$_6O'&J*T5OPPH?B:G`"C2'NXLO;&&2MOMT;:)[]DX/<2#"K7XF.I(1VQK)-5@27>79^ M[-ZXO%[:K:BEP^R-OO,VW.O]N0?PK9^#,S`R3QXV-FDRV5FTCS9"ODJJZ=A= MI?P)=VGEW;-HN+F_A1I=XG`\6YE.N>2G`%SA$'X8HPD:^2]8^[]S?O7,%I9[ M3<2I!R];$^!90#P[6&O$B,&LDA_%-,9)7.2_ET'OL]Z"_5TW\G#M/.4N^>R> MF*JOJ9]KY+;4>^\)C9'+TV*SF.R5+C,O)1(QM3)EJ/(Q-,JV5Y*=6(N23B7] MZKERSDV?8.;(X5&XQW!MY'&"\;(70-ZZ&5@I/`,1PZS\^XESEN,/,7-?(4UR M[;/+:"\BC)JL]^Z]U[W[KW7O?NO M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7_]'?RJ:BGHZ>>KJYHJ:EI89:BIJ)W6*&"G@1I9III7(2.**-2S,2``+G MW>.-Y72*-"TC$``9))P`!YDGATW++'!%)--($A12S,30``5)).``,DG@.M5[ MY]_,JN^3&_SMG:=74T_2^QLA/!MZA62:&+>67IY&@J=XY6G#A986TLF-C=;P MT[&2P>5K='O93VIA]OMD_>&YQ*W-EY&#*U`3`AR($/D>!E(^)J+P4=<;_O*^ M_%Q[M0=NE(@2I`NI5-&NI!7(P1`".U"6PSFA#:2ES.YLM18O&4- M?FLQD'BH<7BL92SUM9-8Z8*.@H:9))/%%JX55TH+L;K,QH*GU)J>`\AUC?!#?[O?6]G9V\MQ?RD)''&I=CZ*B+4T'H!0< M3YGI8YG8E!M"22BWENK&TN?IYO%5[4VL(=UY:@('KBRN6I*N':V-K8F]+TXK M*B:-@0ZJ1;V56F]3[HJS;3MDC6+"JS35A1OFB$&9U/DVA5(R"1T>W_+EOL;/ M!OV\PIN2M1K:WIQM-093'4&[ZJJQ^"S^.K,?6UN/R6-?*4AIIXCXJB!W1]+H253-S M#+9;_M/+^[VL:3W\Y6`(J"*%:G*,.Y\J[]S9 MR_>RRVVU2VZW<,T:I(B7+,D,T;(SI(AD4QNO:Z$J:,I)%F_\FK9D^0[4[/GWK=V2#ESE?9`WZUQ=O, M1_0B31_QZ3^1ZRY^X=L,ESSESOS*5_0M-OCMP?Z=Q)KI^20G]HZV'/>#/74' MHI/R\^6NV/B7LW;VX\Q@*O=V:W5G3AL%MB@R-/BZFJAI:7RDE94P5,<5) MC(6C#>@EI)D4?7W)OMA[9;C[F;M?6%K>K:VEM#XDDS*7`).E$"@@EG-:9P%) MZA/WO][-H]E-AVS=;[;7OK^\N/"AMT=8V8*NJ20LP8!8QIKC)90./2'^''S@ MQ?RYR>_<71=?9#8TVQZ'`USM79ZDS0R<6ZGM!<>V-OLMQ-OB7B7CR+VQM'H,80YJS5KJ^5*=![V)^\+9^]UWS)9P[W#761O7O?NO=>]^Z]U[W[KW0!?)3Y M-],?$GJO,]P]Y[OI=I;/Q+)2TX\/BW`U/UM\4*VLVVLC+!5;[[)HL1GZ^%9" M!4+BL%A,Q1T)DB`/C-3,5/!;VYX?SZKJ^75P'\N/^:ETW_,0HMUX7;VV\WUC MVSL6DI,KN3K;<==299ZG;U9*E'#NC;6>H(H*7,8<9$^"=&CAJ:61D\D>F1': MC*5^SJP-?MZM&]UZWU[W[KW7O?NO=>]^Z]U[W[KW7__2VD_YKOR.K>L^K,3T MUM6N:DW3V_'7+G:JGDT56,Z_Q[1PY1$*D2PR;DK)5HU<'F!*@>\E_NU\A0\P M\QW/-6Y0ZMMVLKX8(P]RU2GR(B4%R/XBG6%?WS_=6?E'DZRY#V:X*;SO@?QF M4T:.R2@D^8,[$1`_P"4=4"=0]0;T[LWE2;)V110&H^VGR>1D^TVYL_;=` MODRNY]S9)@(<=A\73@LQ)URL!'&&=@/>;'-'-.T\H[5)N^\2G1J"1QJ-4L\K M82&).+.YQZ`=S4`ZYH\C\C;_`.X._0\O\O0+XN@R2RN=,%M`F9+B>3@D4:Y/ MFQ[5!8TZ'3M&NQ76G7=!C>BERN/ZUWSELUM2M[>R-.U'O/O.NV7#1?WKR&)J M"$J=H=4TU?EHH*/&4A1Z\ZGK'E*!5!O+L%SS!OTUQSF8WY@LXHYEL5.J#;EG M+>"KCA/>%4+/*]1'A8@M:F1N<+FRY2Y6M[3VY6:+E/<9Y;=]SD73=;N]J%^H M>-L-:[21@J@#/ M$\2?)15B<`$]0[LNR;MS#N=GL?+^V37>ZSL%CAA0L[$FG`<%'FS451EB!U8I MWWUQ2?#OXQ4'0N4K*3+]\_(;/;?WGVA1XJ>.O@VMLW9L\LNV=K4IC4O/+59V MJT^5.*J=)]`*+&3!/)6_2^ZGN'/SI;Q-%R9L4,L%HS@J9IYP!+,U>`$8K0_` MI2N2PZRD]R>58/8KVAMO;:[N$G]R.:+F"ZW!8R'%O:VI)@MUIDEIFIJ']HXD MTU55)ND^`?Q\F^//QXVYALW1K2[YWE(V]]\*1>:FRF7AB^PPTC$!O]P>(CA@ M93^F?RD?6_O$SWKYX3GGGF_N[.4ML]J/I[?T*(3J?_FXY9@?-=/IUGU]VKVQ MD]K_`&OVK;]Q@"JNG-E;XEQ M];3`K#%@MEXNMJLGF(7`93/N_>,<$$+'EJ58R.%]Y^]V^VFVSN>3=AV^[*.O`0VL; MM)*#ZW5T$13YQA3Y=*#^3CGVI^[NQ\)K13N'JR"O16_2T^%W!CR"!<$A$RS7 M_P`#[1?>IL@_*&PWE,0;D5_*2)O^@.C/[B>YF+W"YJV_4`;K9@X'SBF3_`)# MT8;$_P`T#M7$_(>AZ5[,ZJV+MS'TO:2]>;HR]!E=P-7XVGDS38>++TT5:RTK M)()89QK.@Q/>_P"?8%N?N\^YRLO="WY`YMY-VZUMDWGZ*XE22;7&IE\(2J&[:&JOG&DUZ%'='\P MO?&Z_DK)T)\;M@;/W[BL94OC]P;\W/ELK0X;&MAYI#O'<1JL8WVD>TMM4PT_ M[+>VWM3RS8[E90N4FO+B21(D\(GZJ?5'VBV@7&LG]1P0E M05J%OHHVW/DL;N')_WBJZ+4*VJVIM3;SIE9<+ M$8V9*FHE!D3U>,+9B(N5?NUV2[0N\^XG,#;>'`;P4:)/"5OA$TTO8)#7**#0 MXU5J`#N>OOG;G)S!)RY[0\I+NQC)7ZAXYY/'9/C:VMH2)#$*$B1V!(SI`H2M M?A]_,TR?-Z?[BV9A]I[FW)-4T.UL_MILC#BZC-4<,T[X#.8G,5%56XZO MJA3R+#(DKH95\;HA(/LI]TON^V_*G+\_-/*N[2W.WVX#31RZ2XC8@>+&Z`*R MBH+`@&AU`D8Z/_8W[V]YS[S;:\C<];#!9;M=LR6\T&L1M*H),,L-;GJ;; MV[=W&G1O%4UF8W;*U,D]M8QU%$HXO?&51I6O6;Q-3UM0];?R@OAMU?\`%7+] M#S],[/W_`+FS>QJZEW9V3N'$TN4WYN+?53A727<6(W)71_Q+;8I\Q:3&T]') M304:(BZ2=;,UJ-:UZMI%.J9OY._\L[YS_%SY@[;[X[EZVH>L>JL3LCL7;NZJ M[.;[V;59>KHBQ\B\_05N0Q!N#Y&][4_Q9^5G5.)ZB[< MW!D,EA=EYC;=/G\7AZW=6'IZFIK]B[MVMNJ>KSNU]S2Q4@0[T_X4(;^ZB^878_1U-T[UED^G>N.Y*OK_([]?+;PJMW5 M>VMO5]/0;GRE#AZ%DQU5G#/#514,`(BDF$0<@%B-A`16N>M%B#T7+?/_``I0 M^36&[,JI<=\8NOMK];4E>M3#LG?AWO2=FU>V'E,L-16YHU>+Q6/S%=CQJB,> M,EI$D(%Y5!8^$8]>O%O08ZVFJ3Y*;1K?B@_RX@Q.:.QTZ'K>_6P3)`NX?[NX M_8M1ONIP^DR?:G+K14S0#U^(R\WTF_MNF:5ZO7%?+K__T[)OG)O3/=X_,7LB MCQHFRBX+/KUMM2BAO(L6.VI&::L>%0!H2?*_=U,A^OJ_/'OIE[/;38\G>U>P MS7!$?C0?5S,<5:;*U^830@ZXI?>'W[<_<3WVYKM[0--]-<_06R#-$MQI5]B*Q6,)RGC2$UN".!?2A< M$UI5.&GJ3?=G8_\`@?/9K8O;[;&T\[\TAIMTN%P_T\(&FT4\1'KD$9`IJTRD MU#]6[=8?'/X[]O\`Q9^/^U]R[*VWOW9V!V#MW);:GF$\4E%DLIB::;/UE!D, M;4TE=25-?DWE^[5)`))`0X)7C&#F'GOGKE;W&YVW+;]WN++=IKV5)0*'4B.1 M&K*P96"I3148'PG/6;O*'M9[7<\^SGMGL^[]?B)\",=D]I]']?;.KNZ,[&N-H-F[(I8JO+#(SD0 MXX[XW%KK6>3?<_WIGM]SYOWRZ3E.$ZVGN&* MII&7^GB[4+4&7"A%&6;&DQUSK[C>R'W;+2\V7V\Y8L9>?K@"-+6T4-)K.(_J MYZO(JZB*1%FE';1T.GPK"@,BK6,2Z(@6TR'K8,]X0]=-^B'?S$?D-_H%^/N9APU:M- MOSLO[K9&SU4_Y12I64Q_O%G8P5-AAL/*VEK@K430V_PF;V,Y&_KISO:-=1:M MEV^EQ/Z'2?THS_S4<"H\U5NLY_^MM[97\=C/ZT;W(G-V\1O`$6WFD$=ND3+ M&OB*I6LLCL["N*)7AA`?RJLH<1\N]IT+R:%S.Q=[X9Q?B1X<7392)/\`'UXO MCV=?>1MQ=>V&YS!:F*]MW^RKE#_Q_H,_"W#3))CH9L@5'CCGS6)I M:>=0&UV4LP`924WW;]PW*]]MXK:_MI%MK:ZD2"1OADB-&(7U$;EE.*9H*T-% M_P!\K:-FVWWDN+S:KV)KR\L89;F)/BAF4%`7\@98U1P*UQ4@5%1>VYA]H_'K M^67N#M?8V32N[,^1,U#LK-;KBA6GR6$H\KE:S'Y/9E$_D>6"BQ.+Q5:)3Z6J M)YS(1;QZ0O?W6Y\\_>#L>6MXM]'+^Q!IXX2:I(R(K).W`%G=XZ?PJH4?BJ-] MJL=D]L/ND;GSGR[=B3FWFEDM);@"CPK)(R26J&I(2...75PUNY$RO5;-;?GKGFXB7QT>.SB8C M*(J^--0^6K5$#3R6G59NW=R39CY8[@[#VXY@_AW8':W:..FIQH,-%M2BW?O* M.=-(LH-/B@?Z>KW-/.6GE_V1W2"]%7AV*.$@YJ[1QQ@?[T?Y=8V>W.KFW[S. MQ76V8CN>:9;A2,4B6:68G[-"_P`^JF/Y1NU%[>_F5?%[^.LM:?\`2%G.TLJ: MM1,*W(;9V]N'>B/,'!$DLF M2M,Q9XAI4KS[H@6F>/6VK7'#JK_JK^83\RZ_X:?.3?G:GR*[.[`I\[@^KOCE MU]3;ES,,L.%W1VYFLUDMYY_%_;8^F*9*BZYVQ54P?5J1:ZXL?=BHU+CK0)H< M](S^5'W_`/(+XEY+LSMGH;X/;C^4=?N>CQ6P!O3%4.ZS2;#I,4?XOE=M8^NV M]MK/0I59LU5'-5(6BD$<$(-U(][8`X)Z\*C@.A/ZNV7\O.T?YI&S?F;VA\5. MVNG<%5=T_P"FS>LM9L3<]+M+96#V3M*MRV0^[W!EL5CXI(&HMO:7GF6,S336 M(NUO>B0%TUZ]FM:=`]_*3V#2?++^:%UUG]]8VFW#C&W/V3\B=T464IEK**KK ML8:_DBG95#2ST\^\8H06N0%`'``]^C';UYN/6Z=% MT31P?$8_&F*.".C;X[S=*%5-J5.O_ MU+Q_CCU#2K\G^U-T[YI/W(?EQ0]54SUH*QI5Y+)[S[(KU+2C3YT\L->$+QTHL%JO#R3QIG/H4!/#KEE[5&H\L<\+21NRLC)JL MP]QA]WKW2Y;Y*CWO8N9IVM[:ZE26.;260,JE&632"P!&DJP!%00:5'4X?>Z] MC.?7-U^]>TYMD[/H:>9PE34S8S%YFJ>?4&)*QT]Y2;7N;^\ M@=Y]U_9Q[J*Y1(-WWPXC6"S%Q.Q`P`[H`/M+8ZQ)Y=]AOO%1V4UG))=I931]H_)O.82 M;#-4PR.RY'97QYP=>)ZJBRV3B5XJ_P=KO^[SV'*5[//MB' M3N&_S1&+4">^TV6)ZLLD@JLU_(QE1#1%C+`-?WLS9NV.O=K8+96S<-1X#;&V M\=3XO#XF@B$5/24E.NE1QZI9I6N\LCEI)9&9W)9B3A3NVZ[AOFXWF[;K=//N M%PY=W8U+,?\``!P`&`````!UTLV'8=HY8V?;M@V&PCMMHM(A'%&@HJJO^$GB MS&K,Q+,223TIB0H+,0%`)))L`!R22>``/9?QP./1L2`"2<=:QWRFW_E/G#\U M]N=6;)J_O-IX3UIJ283TQQ]+7BHW_O4:-<0B<4L[)+8@T])#<\^^A'M MSLMO[/\`M)?\R;O%HW.:W-W,&%#J9:6T&:1IG/5DU1_*-^*T5-/)'7=LM-'3RLA M;?%/I,J1,59E&!`L7%R!_K>X$C^\[[CM(BM#MFDL/^(YX5_YJ=972_BX4T_QM>-/^:/KU07TYVQ7_`![[CQW8V%IJ7)Y78]9NVAH:*LJ1#32U M-1CLQMZGEK&4,SPTDU0LTB"WE$96ZWN,U.:N68>>.59]ANY&CMKQ(69E%2`& M24A?0L`5!\JUS3KFMR+SK<^V'/=KS380I->[?)U7+]O"NT11-!(R4TI,$K##&0 M:=NDB4T):1Z<0U9CF]D.;-]]F^;_`'VYKN[A]^FG2ZB235KEMC)2XN)0PKWZ M@T"U`6*,M\++1`;#S&;[)^&G:?4>%2IS&3ZC[-VWW?28BA\E;7S[*S./K=K; MNJ*.A@,M1/3[?RDM-5S"-"(XIY)&X%_9WO-K9[![K\N;)N\&[+$E6H%5ST8C^6C\,,MN;%;X[=[*Q>3P6!W+L3=76>PJ3*44 MU+D,E2;RP\V%W/O!:2LCAF^Q7&5+4M'(;"H,DS`Z0"T;?>6]R+&>TBY"V>Z2 M65I5ENV1@RIH),<-5)&K5WN/PT0')-)H^Y=[-[I:[C<>ZO,5C+!;I"T%@DJE M7D,@`EN=+`'1I_3C;\>J0C`%=5*&#OS^53\V<179;;RX?LSH/>M=/A(-Q4M; M!M?L39U1%78A*W'UJ?;'*;7WEM6M8"HI79J>20@VEB9/>'F&'71C@>K!_EK_ M`#+_`)8?S;]IQ?'WJ/H=-C]=;;H\AV=VC2;;S63W8E=2;!Q5=N)\CO7>LN(P MF%VUM'#0T;U$-')%Y:VN6$:Y&6-!4*%R3UXDGRZ3W6GQ*WSV?_(GWOVIU]@\ MAN++4'R^G[HR&)Q5#-6Y3*];;&VE#UODZ[&TM+'+5Y'^"5-?55CQQJY6"&9^ M-)]^U`/3Y=>IV]/W\M3^:QN5PE%M2 MKK]S8/"8NEIMWRU=0,K11X&MPRNPIX*DU4#>-?$XO[\R%C7KP-!T-_17:?\` M,)J/@1\WOF5\J.^>W*CJ/(=.;JZUZ9Z^[`JWQD.]M[=J9.@VO/O+%T.3QE-E M8MI;8ILZ:?$Z)A'5R/(4U1T]W\0NI0!UO-":]*+_`(3']7T^2[9^2_I#P'7EZK=VE7K\S? MYSF+K'F&0H.R?FK4932I2KMLSK_=53707C4NII8ML;+3_:`I_I[MP3\NM<3U MO'?[-9A3WRW2@VCE_$F47`-NDU""+^-LH7PIC!3$&D%0X4DU`J/"?N/#X+.6 M:8KU>O7_U=P3N+"_%3)X?O6FW-N_([=J,MV;UA2;RR.T:#<57N#:_>\=%AUZ M[RNTXL)@LI65N]IJ:3',\5'%6)IC`G5+RWF?E6[]R+>ZY-DV_:XYXXMONV@6 M=HEBFV[4_P!4DQDD15MP1*`7*'/831>L;^>[#V:N[#W%AW;?);66;=]O6ZDM MDG:>WW<)%]#);"&&1GNRI@)6-911?U`*OTN,)UU\OJ&GAQTWR4V)F<0L2"GS MF7Z)\&^)*;0/$:U*?>V-V_\`Q+QVUN]`HUW+1WNOLGN]]]KYG>=.0+R*ZJ:Q MIN-;>OGIK;O+IKP`D..#>?0AV_E;WPMHH[63W7VZXL0HI-+M%+LK3&O3=QP> M)3B3",Y*>70*;ZV7UCB]TT,ORD[AW]N1H99:C!T>X]M[KHL#6,%M74F+J]M[ M.Q>QZ9FC(+18N,Y18@=58T>H>Q9L^[ MX.>!F(A+4I$&IT`.8M@Y1L]YMW]X.>MSNRI+1+/!_-_<);G^\?WA>?O?Q?WGXA\7Q:^)K\]6K-?MZR9V3]S?NC;OZO>!^Y M/"7P?`T^%X=.W1H[=/V>?SZ4?M#T:]<)?'XY/-H\.A_+Y=/C\>DZ_)K].C3> M]^+>]KJU+IKJKBG&ORZJ^G2VNFBF:\*>=?ET%FU?]!_\:@_N1_HI_O%XJG[; M^ZO]T?XUX/&?O/!_"/\`+O%XK^73QI_5Q[$>Y?UO^D?][_O+Z&HKXWC^'6O; M77VUKPKY\.@=LW^M[]?'_5[]S?O32VGZ?Z;Q:4[J>%WTI\5,4X]"J;6-[6MS M?Z6_-_\`#V&^AGT!DW^RT>6;[C_07Y_++]QYO[@>7SZV\_FU^OR^2^O5SJO? MGV,4_K_I3P_WQHH*4^II3RI3RIPZCJ3_`%I=!XO[P\3&G5XFNOE3NU5],U^?0VN/W9^[9/J_`_='A=VO1X/A4\ MZ]GAZ?7MI\ND-M/_`$+?Q*7^XO\`HN_B_P!C/Y_[I_W3_B7\-U1?<^7^#_Y5 M]CKT>2_[=]-_Q[.-S_K;X"_OC]X_2ZQ3QO&TZ\TIKQJXT\^-.@]LO]0/JW_J M[^Y_K_#-?IOIO$\/&JOA=VBM*U[>%?+H(H?]DG_ON?!_LMO]_?N1_F_]'?\` M&_O_`"<:;?N?Q#S?T_>U_P"/L3M_KM?NCO\`W_\`N;3Y_5>'II^S33_:T^70 M(3_@?_ZP?I_U4_K)K\OH?%UU_;KK_MJ_/HUBZ=*Z-.C2-&FVG3;TZ;<:;?2W MN-S6IKQZF84H-/P]%M^1_P#LH_\``J#_`&:[_0)_`M4G\(_TW_W&\&O4OF_@ MW]\/W/)>VO[;G^OOPKY=;Z=.E?\`97?]'>1_V7W_`$'?Z+?#4_QK_13_`''_ M`+F>'[-_O?XY_=C_`'%7^PU>;[KU>*^OT^_9_/KV/+H2]A?Z.O[IT/\`HP_N M5_<;_*_X9_<+^!_W3_X$2_??8_W>_P!P_P#P*U^7Q_[LU:N;^]=>Z);/_P`- M#_1E_=+^'_>?;MX/XS_=;_)ON?M+ MZ//ZO'>W'OW6L>72+V9_LI_][*#_`$>?[+Q_?KRUO\,_N9_HV_O9Y_!/_$?L M/X'_`+F/+]KY?/X^?'JU<7][SUO'2V/^A_\`TH)J_N3_`*7/X:=%_P"&?WN^ 9P^U-]-_\L\O\-O>W[WVG_-KW[-/EU[K_V3\_ ` end